Novo Nordisk's Margin Test: Logistics Win Meets Global Price War
Published on 04/11/2026 at 16:31 | Redaktion boerse-global.de
Novo Nordisk's stock is navigating a complex landscape of operational progress and intense commercial pressure. The European Medicines Agency (EMA) has granted a significant logistical advantage for its weight-loss drug Wegovy, allowing it to be transported for up to 48 hours at controlled temperatures up to 30°C without continuous refrigeration. This makes Wegovy the first GLP-1 weight-loss drug in the EU with such approval, promising lower distribution costs and simpler home delivery for pharmacies and online partners.
This operational boost arrives just as the Danish pharmaceutical giant faces severe pricing headwinds in key markets. In India, where the patent for semaglutid has expired, local manufacturers have flooded the market with cheaper generics, capturing a 33% market share by March. In response, Novo Nordisk slashed prices on April 1, cutting the entry-dose price for Ozempic by 36% and for Wegovy by 48%. This aggressive move helped stabilize its Indian market share at 25%, but such patent expiries have also occurred this year in Canada, Brazil, and China, squeezing revenue.
The company's shares reflect this challenging environment, trading approximately 27% below their 200-day moving average. Since the start of the year, the stock has lost about 28% of its value. Technical support is currently seen near the €37.50 mark. To support the price, a share buyback program of 15 billion Danish kroner, initiated in February 2026, is underway. By early April, roughly 9.97 million B-shares had been repurchased at an average price of 259.47 DKK, with an additional 800,000 shares bought around the recent month-end.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
All eyes are now on the upcoming quarterly report due May 6. Analysts, including those at Swiss bank UBS, will scrutinize the gross margin, estimated at 79%, for the first clear indication of how deeply the price cuts are biting into profitability. The key question is whether unexpectedly strong volume growth for injectable drugs can offset the revenue impact of these discounts.
Competitive dynamics in the oral obesity drug segment add another layer. Novo Nordisk recently presented data from its ORION study, an indirect treatment comparison between its oral Wegovy tablet (25 mg) and Eli Lilly's newly launched orforglipron (marketed as Foundayo in the US). The data favored Novo Nordisk, showing its oral semaglutid was associated with roughly three percentage points greater mean weight loss. The tolerability difference was more stark, with patients on orforglipron having about a 14-times higher likelihood of discontinuing treatment due to gastrointestinal side effects.
However, the company's pipeline suffered a notable setback. The Phase 3 EVOKE and EVOKE+ trials, investigating oral semaglutid for early Alzheimer's disease, failed to meet their primary endpoints in November 2025, showing no superiority over placebo on the CDR-SB clinical scale. The extension phases were halted, marking a disappointment for the long-term evaluation of semaglutid beyond metabolic indications.
The coming quarters will reveal if operational efficiencies and competitive clinical data can counterbalance the global price erosion and pipeline challenges now defining Novo Nordisk's investment story.
Ad
Novo Nordisk Stock: New Analysis - 11 April
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
